Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome;Dosage et spécificité d'autoanticorps anti-canaux calcium dans le syndrome myasthénique de Lambert-Eaton

Revue Neurologique

Volumn 160, Issue 5 II, 2004, Pages

  Martin Moutot, N ^a   De Haro, L ^a   Seagar, M ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Autoantibody; Calcium channel; Lambert Eaton syndrome

Indexed keywords

AUTOANTIBODY; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; IODINE 125; OMEGA CONOTOXIN GVIA I 125; OMEGA CONOTOXIN MVIIC I 125; UNCLASSIFIED DRUG; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIAGNOSTIC AGENT; OMEGA CONOTOXIN; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIC; OMEGA-CONOTOXIN-MVIIC; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DOWN REGULATION; EATON LAMBERT SYNDROME; HUMAN; IMMUNOPRECIPITATION; ISOTOPE LABELING; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; NERVE ENDING; NEUROTRANSMITTER RELEASE; PROTEIN EXPRESSION; SEROLOGY; ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PRESCHOOL CHILD; RAT; SERODIAGNOSIS;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM CHANNELS, N-TYPE; CALCIUM CHANNELS, P-TYPE; CALCIUM CHANNELS, Q-TYPE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MALE; MIDDLE AGED; OMEGA-CONOTOXIN GVIA; OMEGA-CONOTOXINS; PRECIPITIN TESTS; RADIOPHARMACEUTICALS; RATS; SEROLOGIC TESTS;

EID: 2942735440     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. BADY B, VIAL C, CHAUPLANNAZ G. (1992). Syndrome de Lambert-Eaton: étude clinique et électrophysiologique de 18 cas associés à un cancer du poumon. Rev Neurol, 148: 513-519.
2. BENATAR M, BLAES F, JOHNSTON I et al. (2001). Presynaptic neuronal antigens expressed by a small cell carcinoma line. J Neuroimmunol, 113: 153-162.
3. CODIGNOLA A, TARRONI P, CLEMENTI F et al. (1993). Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem, 268: 26240-26247.
4. CULL-CANDY SG, MILEDI R, TRAUTMANN A, UCHITEL OD. (1980). On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol (Lond), 299: 621-638.
5. DAVID P, EL FAR O, MARTIN-MOUTOT N, POUPON MF, TAKAHASHI M, SEAGAR M. (1993). Expression of synaptotagmin and syntaxin associated with N-type calcium channels in small cell lung cancer. FEBS Lett, 326: 135-139.
6. EL FAR O, MARQUÈZE B, LÉVÈQUE C et al. (1995). Antigens associated with N- and L-Type calcium channels in Lambert-Eaton Myasthenic Syndrome. J Neurochem, 64: 1696-1702.
7. ELRINGTON G, NEWSOM-DAVIS J. (1994). Clinical presentation and current immunology of the Lambert-Eaton myasthenic syndrome. In Handbook of Myasthenia Gravis and Myasthenic Syndromes pp81-164, Marcel Dekker Inc. New York.
8. FUKUNAGA H, ENGEL AG, LANG B, NEWSOM-DAVIS J, VINCENT A. (1983). Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA, 80: 7636-7640.
9. GARCIA KD, BEAM KG. (1996). Reduction of calcium currents by Lambert-Eaton syndrome sera: motoneurons are preferentially affected, and L-type currents are spared. J Neurosci, 16: 4903-4913.
10. GARCIA KD, MYNLIEFF M, SANDERS DB, BEAM KG, WALROND JP. (1996). Lambert-Eaton sera reduce low-voltage and high-voltage activated Ca2+ currents in murine dorsal root ganglion neurons. Proc Natl Acad Sci USA, 93: 9264-9269.
11. KIM YI, NEHER E. (1988). IgG from patients with Lambert-Eaton syndrome blocks voltage-dependent calcium channels. Science, 239: 405-408.
12. LANG B, NEWSOM-DAVIS J, PEERS C, PRIOR C, WRAY D. (1987). The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol (Lond), 390: 257-270.
13. LANG B, NEWSOM-DAVIS J, WRAY DW. (1988). The effect of Lambert-Eaton myasthenic syndrom antibody on slow action potentials in mouse cardiac ventricle. Proc R Soc Lond, B 235: 103-110.
14. LANG B, VINCENT A, MURRAY M, NEWSOM-DAVIS J. (1989). Lambert-Eaton myasthénic syndrome/immunoglobulin G inhibition of Ca flux in tumor cells correlates with disease severity. Ann Neurol, 25: 265-271.
15. LENNON V, KRYZER T, GRIESMANN G et al. (1995). Calcium-channel antibodies in the Lambert-eaton syndrome and other paraneoplastic syndromes. N Engl J Med, 133: 95-101.
16. LÉVÊQUE C, HOSHINO T, DAVID P et al. (1992). The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc Natl Acad Sci USA, 89: 3625-3629.
17. LEYS K, LANG B, JOHNSTON I, NEWSOM-DAVIS J. (1991). Calcium Channel Autoantibodies in the Lambert-Eaton Myasthenic Syndrome. Ann Neurol, 1999: 307-314.
18. MADDISON P, LANG B, MILLS K, NEWSOM-DAVIS J. (2001). Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry, 70: 212-217.
19. MARTIN-MOUTOT N, LÉVÊQUE C, SATO K, KATO R, TAKAHASHI M, SEAGAR M. (1995). Properties of omega conotoxin MVIIC receptors associated with alpha 1A calcium channel subunits in rat brain. FEBS Lett, 366: 21-25.
20. MOTOMURA M, LANG B, JOHNSTON I, PALACE J, VINCENT A, NEWSOM-DAVIS J. (1997). Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Science, 147: 34-42.
21. NAKAO Y, MOTOMURA M, SUENAGA A et al. (1999). Specificity of ω-conotoxin MVIIC-binding and -blocking calcium channel antibodies in Lambert-Eaton myasthenic syndrome. J Neurol, 246: 38-44.
22. NEWSOM-DAVIS J, MURRAY NMF. (1984). Plasma exchange and immunosuppressant drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology, 34: 480-485.
23. OLIVERA BM, MILJANICH GP, RAMACHANDRAN J, ADAMS ME. (1994). Calcium channel diversity and neurotransmifter release: the omega-conotoxins and omega-agatoxins. Annu Rev Biochem, 63: 823-867.
24. O'NEILL JH, MURRAY NMF, NEWSOM-DAVIS J. (1988). The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain, 111: 577-596.
25. PARSONS K, KWOK W. (2002). Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J Neuroimmunol, 126: 190-195.
26. PEERS C, JOHNSTON I, LANG B, WRAY D. (1993). Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction. Neurosci Lett, 158: 45-48.
27. PEERS C, LANG B, NEWSOM-DAVIS J, WRAY DW. (1990). Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line. J Physiol (Lond), 421: 293-308.
28. PELUCCHI A, CICERI E, CLEMENTI F, MARRAZZINI L, FORESI A, SHER E. (1993). Calcium channel autoantibodies in myasthenic syndrome and small cell lung cancer. Am Rev Respir Dis, 147: 1229-1232.
29. PINTO A, GILLARD S, MOSS F et al. (1998). Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc Natl Acad Sci USA, 95: 8328-8333.
30. PINTO A, IWASA K, NEWLAND C, NEWSOM-DAVIS J, LANG B. (2002). The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve, 25: 715-724.
31. RAYMOND C, WALKER D, BICHET D et al. (1999). Antibodies against the β subunit of voltage-dependent calcium channels in Lambert-Eaton Myasthenic syndrome. Neuroscience, 89: 269-277.
32. 2+ flux in a human small cell carcinoma line. Nature, 317: 737-739.
33. TAKAMORI M, TAKAHASHI M, YASUKAWA Y et al. (1995). Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci, 133: 95-101.
34. TAKAMORI M, MARUTA T, KOMAI K. (2000). Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosc Res, 36: 183-191.
35. Verschuuren J, Dalmau J, Tunkel R et al. (1998). Antibodies against the calcium channel β-subunit in Lambert-Eaton myasthenic syndrome. Neurology, 50: 475-479.
36. Waterman SA. (2001). Autonomic dysfunction in Lambert-Eaton myasthenic syndrome. Clin Auton Res, 11: 145-154.